Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 14Sanofi-Aventis Canada Inc.

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2737044

Filing Date : 2009-10-27

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2029-10-27

Date Granted : 2017-02-28

blank

02

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2813587

Filing Date : 2011-10-05

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2031-10-05

Date Granted : 2019-01-15

blank

03

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2883936

Filing Date : 2013-09-04

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2033-09-04

Date Granted : 2022-01-11

blank

04

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2917804

Filing Date : 2014-07-10

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2034-07-10

Date Granted : 2021-11-16

blank

05

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2737044

Filing Date : 2009-10-27

Strength per Unit : 200mg / 1.14mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2029-10-27

Date Granted : 2017-02-28

blank

06

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2813587

Filing Date : 2011-10-05

Strength per Unit : 200mg / 1.14mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2031-10-05

Date Granted : 2019-01-15

blank

07

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2883936

Filing Date : 2013-09-04

Strength per Unit : 200mg / 1.14mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2033-09-04

Date Granted : 2022-01-11

blank

08

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2737044

Filing Date : 2009-10-27

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2029-10-27

Date Granted : 2017-02-28

blank

09

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2813587

Filing Date : 2011-10-05

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2031-10-05

Date Granted : 2019-01-15

blank

10

Sanofi-Aventis Canada Inc.

arrow
Peptide Process CMC
Not Confirmed

Sanofi-Aventis Canada Inc.

Country
arrow
Peptide Process CMC
Not Confirmed

Dupilumab

Brand Name : DUPIXENT

Patent Number : 2883936

Filing Date : 2013-09-04

Strength per Unit : 150 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2033-09-04

Date Granted : 2022-01-11

blank